---
title: "Balaxi Pharmaceuticals Ltd (BALAXI) — Share Price, Financials & Analysis"
symbol: "BALAXI"
company: "Balaxi Pharmaceuticals Ltd"
canonical: "https://tapetide.com/stocks/BALAXI"
isin: "INE618N01022"
nse_symbol: "BALAXI"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 127.64
generated_at: "2026-09-13T19:21:32.673Z"
---

# Balaxi Pharmaceuticals Ltd (BALAXI)

Canonical page: https://tapetide.com/stocks/BALAXI

## Company

- **NSE Symbol:** BALAXI
- **ISIN:** INE618N01022
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2015-11-30
- **Face Value:** ₹2
- **F&O Eligible:** No
- **Website:** balaxiventures.in

## About

Balaxi Pharmaceuticals Ltd is an IPR-based pharmaceutical Company engaged in producing, stocking, selling, and supplying branded and generic medicines. [1]

## Latest Price

- **Price:** ₹23.39
- **Change:** +0.15 (+0.65%)
- **Open:** ₹23.4
- **Day High:** ₹24.69
- **Day Low:** ₹22.75
- **Previous Close:** ₹23.24
- **Volume:** 39705
- **As Of:** 2026-09-11T09:59:54+00:00

## Key Fundamentals

Observed at 2026-09-11T04:50:46.553581Z.

- **Market Cap:** ₹127.64 Cr
- **Classification:** Microcap
- **P/E (reported):** 52.8
- **P/E (TTM):** 51.98
- **EPS (TTM):** ₹0.45
- **Book Value:** ₹45.12
- **Price to Book:** 0.52
- **Dividend Yield:** 2.15%
- **ROE:** 10.82%
- **ROCE:** 12.35%
- **Debt to Equity:** 0.23
- **Revenue (yearly):** ₹270.17 Cr
- **Net Income:** ₹1.85 Cr
- **EBITDA:** ₹8.52 Cr
- **52-Week High:** ₹47.71
- **52-Week Low:** ₹15.2
- **RSI (14):** 46.51

## Tapetide Score

- **Score:** 46 / 100
- **Score date:** 2026-09-04
- **Archetype:** Trend Ahead of Fundamentals
- **What it means:** The price trend is running ahead of what the financials currently support. Moves like this depend on the fundamentals catching up; check what would have to be true for that.
- **Pillar profile:** Quality: Weak · Valuation: Expensive · Momentum: Rising
- **Percentile:** 31.9 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 47.24 | 9% |
| growth | 29.06 | 9% |
| momentum | 75.22 | 12% |
| ownership | 50 | 24% |
| quality | 44.57 | 22% |
| valuation | 40.83 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Stock is trading at 0.52 times its book value

### Weaknesses

- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 3.15% over past five years.
- Company has a low return on equity of -3.58% over last 3 years.
- Company might be capitalizing the interest cost
- Earnings include an other income of Rs.3.62 Cr.
- Company has high debtors of 184 days.
- Promoter holding has decreased over last 3 years: -5.23%

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | -818.69% | -675.66% | -35% |
| ebitda margin growth | 23.33% | -72.54% | -82.88% | -83.92% |
| net income growth | 116.67% | -92.63% | -69% | -48% |
| revenue growth | 8.29% | -8.39% | -7% | 3% |
| roce | 17.99% | 582.32% | -59.88% | 32.29% |
| roe | 113.11% | — | 11.59% | -81.56% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 54.72 | 60.79 | 59.83 | 65.62 | 77.38 | 73.29 | 76.27 | 70.74 | 56.18 | 72.54 | 70.71 | 80.68 |
| Expenses | 43.96 | 47.14 | 46.36 | 55.53 | 66.79 | 69.3 | 63.72 | 66.58 | 55.02 | 69.45 | 70.59 | 76.02 |
| Operating Profit | 10.76 | 13.65 | 13.47 | 10.09 | 10.59 | 3.99 | 12.55 | 4.16 | 1.16 | 3.09 | 0.12 | 4.66 |
| OPM % | 19.66 | 22.45 | 22.51 | 15.38 | 13.69 | 5.44 | 16.45 | 5.88 | 2.06 | 4.26 | 0.17 | 5.78 |
| Other Income | 5.93 | 1.51 | -0.7 | -1.85 | -4.11 | 3.94 | -1.69 | -1.78 | 1.59 | 0.1 | 2.92 | -0.99 |
| Interest | 0.37 | 0.41 | 0.61 | 0.37 | 0.45 | 1.38 | 0.74 | 1.01 | 0.89 | 1.02 | 0.99 | 0.73 |
| Depreciation | 0.66 | 0.48 | 0.67 | 0.49 | 0.46 | 0.48 | 0.46 | 0.46 | 0.48 | 0.56 | 0.65 | 0.85 |
| Profit before tax | 15.66 | 14.27 | 11.49 | 7.38 | 5.57 | 6.07 | 9.66 | 0.91 | 1.38 | 1.61 | 1.4 | 2.09 |
| Tax % | 7.92 | 4.77 | 4.87 | 12.06 | 17.41 | 11.7 | 10.56 | 67.03 | 84.06 | 80.75 | 56.43 | 38.28 |
| Net Profit | 14.43 | 13.59 | 10.93 | 6.48 | 4.59 | 5.36 | 8.64 | 0.29 | 0.21 | 0.31 | 0.61 | 1.3 |
| EPS in Rs | 2.82 | 2.65 | 2.01 | 1.17 | 0.83 | 0.97 | 1.57 | 0.05 | 0.04 | 0.06 | 0.11 | 0.24 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 14 | 46 | 231 | 279 | 336 | 241 | 293 | 270 | 280 |
| Expenses | 12 | 37 | 189 | 229 | 279 | 197 | 260 | 262 | 271 |
| Operating Profit | 2 | 8 | 43 | 51 | 57 | 45 | 32 | 9 | 9 |
| OPM % | 11 | 18 | 18 | 18 | 17 | 18 | 11 | 3.2 | 3.2 |
| Other Income | 1 | 1 | 2 | 5 | 3 | -38 | 2 | 3 | 4 |
| Interest | 0 | 0 | 0 | 1 | 1 | 3 | 4 | 4 | 4 |
| Depreciation | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 | 3 |
| Profit before tax | 2 | 9 | 44 | 55 | 57 | 2 | 29 | 5 | 6 |
| Tax % | 19 | 31 | 14 | 13 | 19 | 219 | 13 | 73 | — |
| Net Profit | 2 | 6 | 38 | 48 | 46 | -2 | 25 | 1 | 2 |
| EPS in Rs | 1.3 | 1.22 | 7.63 | 9.53 | 9.03 | -0.44 | 4.54 | 0.26 | 0.45 |
| Dividend Payout % | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 3 | 10 | 10 | 10 | 10 | 11 | 11 | 11 |
| Reserves | 0 | 18 | 55 | 103 | 173 | 190 | 221 | 238 |
| Borrowings | 0 | 0 | 4 | 4 | 13 | 19 | 53 | 58 |
| Other Liabilities | 3 | 8 | 31 | 60 | 43 | 38 | 25 | 30 |
| Total Liabilities | 6 | 36 | 100 | 176 | 240 | 258 | 310 | 337 |
| Fixed Assets | 0 | 0 | 2 | 29 | 41 | 41 | 41 | 82 |
| CWIP | 0 | 0 | 0 | 1 | 3 | 2 | 22 | 0 |
| Investments | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 6 | 36 | 94 | 147 | 195 | 215 | 247 | 255 |
| Total Assets | 6 | 36 | 100 | 176 | 240 | 258 | 310 | 337 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | -2 | -14 | 0 | 34 | 6 | 5 | -35 | -4 |
| Cash from Investing Activity | 0 | 0 | -6 | -28 | -11 | -1 | -22 | -21 |
| Cash from Financing Activity | 0 | 18 | 4 | 0 | 26 | 30 | 34 | 0 |
| Net Cash Flow | -2 | 4 | -2 | 6 | 21 | 34 | -23 | -25 |
| Free Cash Flow | -2 | -14 | -3 | 7 | -9 | 4 | -57 | -25 |
| CFO/OP | -97 | -161 | 6 | 78 | 32 | 26 | -98 | 3 |

### Ratios

| Item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 147 | 238 | 121 | 36 | 57 | 84 | 138 | 184 |
| Inventory Days | — | 9 | 29 | 184 | 189 | 233 | 173 | 202 |
| Days Payable | — | 64 | 53 | 92 | 62 | 82 | 36 | 51 |
| Cash Conversion Cycle | 147 | 183 | 97 | 129 | 184 | 235 | 275 | 335 |
| Working Capital Days | 82 | 181 | 91 | 92 | 122 | 142 | 186 | 236 |
| ROCE % | — | 57 | 93 | 60 | 37 | 21 | 13 | 3 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 71.22% | 71.22% | 66.36% | 65.99% | 65.99% | 65.99% | 65.99% | 65.99% | 65.99% | 65.99% | 65.99% | 65.99% |
| FIIs | 18.57% | 18.57% | 17.21% | 16.88% | 16.48% | 16.48% | 16.02% | 8.87% | 3.5% | 1.74% | 0% | 0% |
| DIIs | 0.03% | 0.03% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 2.56% | 2.56% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 6.62% | 6.63% | 7.98% | 8.6% | 9.24% | 9.69% | 9.82% | 16.14% | 20.03% | 22.39% | 24.41% | 24.43% |
| Others | 3.56% | 3.55% | 8.43% | 8.5% | 8.26% | 7.81% | 8.15% | 8.97% | 10.45% | 9.86% | 7.03% | 7.02% |
| No. of Shareholders | 5047 | 5045 | 5132 | 6586 | 7863 | 8529 | 9994 | 13737 | 14620 | 15085 | 15176 | 14682 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 2 / 7 / 10

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 23.92 | Sell |
| EMA (10) | 23.68 | Sell |
| SMA (20) | 23.43 | Sell |
| EMA (20) | 23.66 | Sell |
| SMA (50) | 23.82 | Sell |
| EMA (50) | 23.78 | Sell |
| SMA (100) | 24.52 | Sell |
| EMA (100) | 24.3 | Sell |
| SMA (200) | 24.7 | Sell |
| EMA (200) | 27.91 | Sell |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 47.71 | Neutral |
| MACD (12,26,9) | 0 | Buy |
| Stochastic (14,3,3) | 28.65 | Neutral |
| ADX (14) | 20.63 | Neutral |
| Williams %R (14) | -72.29 | Neutral |
| ATR (14) | 1.45 | High Volatility |
| ROC (12) | 4.37 | Buy |
| Stoch RSI (14) | 37.28 | Neutral |
| UO (7,14,28) | 37.46 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-07 | [Updates](https://nsearchives.nseindia.com/corporate/BALAXI_07092026171128_NSE_Announcement_07092026.pdf) |
| 2026-08-31 | [General Updates](https://nsearchives.nseindia.com/corporate/BALAXI_31082026125652_NSE_Announcement_WHO_GMP_Approval_31082026.pdf) |
| 2026-08-24 | [Shareholders meeting](https://nsearchives.nseindia.com/corporate/BALAXI_24082026231509_NSE_Announcement_for_Voting_Results_24082026.pdf) |
| 2026-08-24 | [Shareholders meeting](https://nsearchives.nseindia.com/corporate/BALAXI_24082026225525_NSE_Announcement_Proceedings_of_AGM_24082026.pdf) |
| 2026-08-24 | [Change in Director(s)](https://nsearchives.nseindia.com/corporate/BALAXI_24082026233553_NSE_Announcement_24082026.pdf) |
| 2026-08-14 | [Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/BALAXI_14082026124418_Balaxi_NSE_Announcement_14082026.pdf) |
| 2026-08-11 | [Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/BALAXI_11082026111357_Balaxi_NSE_Announcement_11082026.pdf) |
| 2026-08-10 | [Corrigendum](https://nsearchives.nseindia.com/corporate/BALAXI_10082026121632_Balaxi_NSE_Announcement_for_Corrigendum_to_AGM_Notice_10082026.pdf) |
| 2026-08-07 | [Updates](https://nsearchives.nseindia.com/corporate/BALAXI_07082026220535_NSE_Announcement_07082026.pdf) |
| 2026-08-06 | [Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/BALAXI_06082026131709_Balaxi_NSE_Announcement_06082026.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-08-06 | [Investor Presentation](https://nsearchives.nseindia.com/corporate/BALAXI_06082026161650_Balaxi_NSE_Announcement_06082026.pdf) |
| 2026-05-29 | [Investor Presentation](https://nsearchives.nseindia.com/corporate/BALAXI_29052026163006_NSE_Announcement_for_Investor_Presentation.pdf) |
| 2026-01-29 | [Investor Presentation](https://nsearchives.nseindia.com/corporate/BALAXI_29012026144532_PRESENTATION_Q3.pdf) |
| 2025-11-14 | [Investor Presentation](https://nsearchives.nseindia.com/corporate/BALAXI_14112025151312_INVESTOR_PRESENTATION.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-05 | [Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/BALAXI_05082026134948_Balaxi_Outcome_of_BM_05082026.pdf) |
| 2026-08-05 | [Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/BALAXI_05082026135358_Balaxi_Outcome_of_BM_05082026.pdf) |
| 2026-05-28 | [Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/BALAXI_28052026192053_Outcome_of_BM.pdf) |
| 2026-05-28 | [Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/BALAXI_28052026192842_Outcome_of_BM.pdf) |
| 2026-03-25 | [Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/BALAXI_25032026130639_Outcome_of_Board_Meeting.pdf) |
| 2026-01-28 | [Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/BALAXI_28012026144621_28012026.pdf) |
| 2025-11-11 | [Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/BALAXI_11112025143926_OUTCOME_OF_BOARD_MEETING.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 24 June 2026 - Exchange has sought clarification from BALAXI PHARMACEUTICALS LIMITED for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015. On … | [Clarification - Financial Results 24 June 2026 - Exchange has sought clarification from BALAXI PHARMACEUTICALS LIMITED for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015. On …](https://www.nseindia.com/get-quotes/equity?symbol=BALAXI) |
| 14 Feb - Copy of Newspaper Advertisement of Un-audited Financial Results (Standalone and Consolidated) for the quarter ended December 31, 2025 | [Announcement under Regulation 30 (LODR)-Newspaper Publication 14 Feb - Copy of Newspaper Advertisement of Un-audited Financial Results (Standalone and Consolidated) for the quarter ended December 31, 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4d29ee7a-5931-40eb-b7aa-fa2682b0af5f.pdf) |
| 13 Feb - Audio of Q3 FY2025-26 earnings call (13 Feb 2026) uploaded to company's investor website. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 13 Feb - Audio of Q3 FY2025-26 earnings call (13 Feb 2026) uploaded to company's investor website.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/bd8a09c1-9a3c-4599-809b-cdfaecebe4c1.pdf) |
| 12 Feb - Unaudited Q3 FY26 results: Consolidated revenue INR 4,789.25m; profit INR 1,368.48m; limited review unmodified. | [Considered And Approve Un-Audited Financial Results (Standalone And Consolidated) For The Quarter Ended December 31, 2025 12 Feb - Unaudited Q3 FY26 results: Consolidated revenue INR 4,789.25m; profit INR 1,368.48m; limited review unmodified.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/60db1576-511c-4159-a30e-a3a282bc3087.pdf) |
| 12 Feb - Q3FY26 consolidated PAT Rs.1,368m (up 35.3% YoY); system-wide sales Rs.8,754m; 530+ units. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 12 Feb - Q3FY26 consolidated PAT Rs.1,368m (up 35.3% YoY); system-wide sales Rs.8,754m; 530+ units.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/8015de85-0f8e-4716-b716-1a590182c784.pdf) |
| 12 Feb - Investor Presentation on Q3 & 9MFY26 Financial Results | [Announcement under Regulation 30 (LODR)-Investor Presentation 12 Feb - Investor Presentation on Q3 & 9MFY26 Financial Results](https://www.bseindia.com/xml-data/corpfiling/AttachHis/cf1d8940-9da4-4fa1-8c10-5bda465af5b0.pdf) |
| — | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript 19 Feb](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a34eae52-037f-4a76-aa35-15db70915fed.pdf) |
| — | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 18 Feb](https://www.bseindia.com/xml-data/corpfiling/AttachHis/204e14ff-c66c-493e-9540-cb61a58c8138.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Oct 2020 | [Concall - Oct 2020](https://archives.nseindia.com/corporate/BALAXI_12102020155500_NSE_Investor_Presentation_12102020.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b1ea6a41-2b55-4a4a-9da8-019051bf68c5.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://nsearchives.nseindia.com/corporate/BALAXI_13112024171136_Balaxi_Pharmaceuticals_Ltd.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://nsearchives.nseindia.com/corporate/BALAXI_02112023162325_Intimation_InvestorPresentation.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://archives.nseindia.com/corporate/BALAXI_15112022152836_Intimationfortranscript.pdf) |
| Nov 2021 | [Concall - Nov 2021](https://archives.nseindia.com/corporate/BALAXI_02112021144536_BPL_Q2_Investor_Presentation.pdf) |
| May 2024 | [Concall - May 2024](https://nsearchives.nseindia.com/corporate/BALAXI_30052024120619_Intimation.pdf) |
| May 2023 | [Concall - May 2023](https://archives.nseindia.com/corporate/BALAXI_29052023164512_Intimation_IP.pdf) |
| May 2021 | [Concall - May 2021](https://archives.nseindia.com/corporate/BALAXI_26052021172659_Investor_presentation_Q4_and_FY2021.pdf) |
| Jun 2025 | [Concall - Jun 2025](https://nsearchives.nseindia.com/corporate/BALAXI_07062025114726_07062025.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2026 from nse](https://archives.nseindia.com/annual_reports/AR_30088_BALAXI_2025_2026_A_5870617_31072026125210.pdf) |
| from nse | [Annual Report 2025 from nse](https://archives.nseindia.com/annual_reports/AR_27198_BALAXI_2024_2025_A_31072025170130.pdf) |
| from nse | [Annual Report 2024 from nse](https://archives.nseindia.com/annual_reports/AR_24749_BALAXI_2023_2024_31072024172757.pdf) |
| from nse | [Annual Report 2023 from nse](https://archives.nseindia.com/annual_reports/AR_22586_BALAXI_2022_2023_01082023105713_08012023110000.zip) |
| from nse | [Annual Report 2022 from nse](https://archives.nseindia.com/annual_reports/AR_20074_BALAXI_2021_2022_18062022171557_06182022180003.zip) |
| from nse | [Annual Report 2021 from nse](https://archives.nseindia.com/annual_reports/AR_18563_BALAXI_2020_2021_30072021213326_03082021194646.zip) |
| from nse | [Annual Report 2020 from nse](https://archives.nseindia.com/annual_reports/AR_16788_BALAXI_2019_2020_19082020180011_19082020190001.zip) |
| from nse | [Annual Report 2019 from nse](https://archives.nseindia.com/annual_reports/AR_16021_BALAXI_2018_2019_19092019150244_19092019160003.zip) |
| from nse | [Annual Report 2018 from nse](https://archives.nseindia.com/annual_reports/AR_13495_BALAXI_2017_2018_20092018175321.zip) |
| from nse | [Annual Report 2017 from nse](https://archives.nseindia.com/annual_reports/AR_11845_BALAXI_2016_2017_01102017092548.zip) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:21:32.673Z.